

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re* Application of: )  
STAGLIANO ) Group Art Unit: 1641  
Serial No. 10/753,267 ) Examiner: David J. Venci  
Filed: January 8, 2004 ) Atty. Dkt. No. 004974.01168

For: **Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419**

**RESPONSE TO RESTRICTION REQUIREMENT**

U.S. Patent and Trademark Office  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This paper responds to the restriction requirement mailed September 25, 2006. Charge the fee for a one-month extension of time to our Deposit Account No. 19-0733.

Applicants elect invention group I, claims 1-11, and the following species: polypeptide 6169, a membrane-bound peptide, atherosclerosis, a competition binding assay, polypeptide activity (aberration), and polypeptide (modulator).

Claims 1-11 read on the elected species.

The restriction requirement included a Notice to Comply with Sequence Listing Requirements. The Notice asserted the specification and claims fail to identify sequences by

sequence number that correspond to those sequences submitted in the sequence listing. Applicants' representative has reviewed the specification and claims. Neither the specification nor the claims contain unidentified sequences.

Respectfully submitted,  
BANNER & WITCOFF, LTD.

/Lisa M. Hemmendinger/

Date: November 27, 2006

---

Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907